<DOC>
	<DOCNO>NCT00307255</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , paclitaxel albumin-stabilized nanoparticle formulation gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I trial study side effect best dose paclitaxel albumin-stabilized nanoparticle formulation give together gemcitabine treat patient advanced metastatic solid tumor .</brief_summary>
	<brief_title>Paclitaxel Albumin-Stabilized Nanoparticle Formulation Gemcitabine Treating Patients With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine dose-limiting toxicity maximum tolerate dose paclitaxel albumin-stabilized nanoparticle formulation ( Abraxane ) combination gemcitabine hydrochloride patient advance metastatic solid tumor . Secondary - Evaluate efficacy regimen patient . OUTLINE : This dose-escalation study paclitaxel albumin-stabilized nanoparticle formulation ( Abraxane ) . Patients receive paclitaxel albumin-stabilized nanoparticle formulation ( Abraxane ) IV 30 minute day 1 follow gemcitabine hydrochloride IV 30 minute day 1 8 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos paclitaxel albumin-stabilized nanoparticle formulation ( Abraxane ) maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Up 10 additional patient may treat MTD . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm solid tumor Advanced metastatic disease Measurable evaluable disease Must meet 1 follow criterion : Failed prior standard therapy Not candidate standard therapy Has disease define standard therapy No symptomatic brain metastasis PATIENT CHARACTERISTICS : ECOG functional status 02 Life expectancy ≥ 8 week Absolute neutrophil count ≥ 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Bilirubin normal Creatinine ≤ 1.5 time upper limit normal ( ULN ) OR creatinine clearance ≥ 60 mL/min AST ALT ≤ 2.5 time ULN Not pregnant nursing Negative pregnancy test No prior anaphylactic reaction severe allergic reaction paclitaxel , docetaxel , gemcitabine hydrochloride No active infectious process require treatment antibiotic &gt; 4 week No uncontrolled congestive heart failure No symptomatic coronary artery disease heart block No myocardial infarction within past 3 month No peripheral neuropathy ≥ grade 2 cause PRIOR CONCURRENT THERAPY : More 3 week since prior chemotherapy , radiotherapy , treatment No prior radiotherapy &gt; 25 % bone marrow No prior nitrosoureas No 6 prior course alkylating agent No 2 prior course mitomycin C No 3 prior course cytotoxic therapy metastatic disease No concurrent filgrastim ( GCSF ) , pegfilgrastim , sargramostim ( GMCSF ) study course 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>unspecified adult solid tumor</keyword>
	<keyword>protocol specific</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Phase I</keyword>
	<keyword>Lineberger</keyword>
</DOC>